Evidence map›Paper›PMID 37752923›Full record

ArticleFuture science OA2023

Epidemiology of bone tumors in Lebanon: a retrospective study from 2000 to 2022 at a tertiary center.

Mohammad Daher, Ziad Zalaquett, Elio Mekhael, Marven Aoun, Ralph Chalhoub, Majd Abdo, Marc Aoude, Sami Abi Farraj, Ali Ghoul, Jean Tarchichi and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Future science OA, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Mohammad DaherHôtel Dieu de France, Orthopedic Department, Beirut, Lebanon.ORCID https://orcid.org/0000-0002-9256-9952
Ziad ZalaquettHôtel Dieu de France, Hematology-Oncology Department, Beirut, Lebanon.
Elio MekhaelHôtel Dieu de France, Orthopedic Department, Beirut, Lebanon.
Marven AounHôtel Dieu de France, Orthopedic Department, Beirut, Lebanon.
Ralph ChalhoubHôtel Dieu de France, Hematology-Oncology Department, Beirut, Lebanon.
Majd AbdoHôtel Dieu de France, Hematology-Oncology Department, Beirut, Lebanon.
Marc AoudeHôtel Dieu de France, Hematology-Oncology Department, Beirut, Lebanon.
Sami Abi FarrajHôtel Dieu de France, Orthopedic Department, Beirut, Lebanon.
Ali GhoulHôtel Dieu de France, Orthopedic Department, Beirut, Lebanon.
Jean TarchichiHôtel Dieu de France, Orthopedic Department, Beirut, Lebanon.
Joe RassiHôtel Dieu de France, Orthopedic Department, Beirut, Lebanon.
Amer SebaalyHôtel Dieu de France, Orthopedic Department, Beirut, Lebanon.
Viviane Trak-SmayraHôtel Dieu de France, Pathology Department, Beirut, Lebanon.
Carole KesrouaniHôtel Dieu de France, Pathology Department, Beirut, Lebanon.
Hampig-Raphaël KourieHôtel Dieu de France, Hematology-Oncology Department, Beirut, Lebanon.
Ismat GhanemHôtel Dieu de France, Orthopedic Department, Beirut, Lebanon.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aim: Bone tumors are rare and have an uneven geographic distribution. Methods: 730 patients diagnosed with bone tumors were included in this retrospective analysis. Results: With a 64% rate of malignancy, the most common tumors were metastasis (40%) mostly in the axial skeleton, Osteosarcoma (9%) mostly in the femur, Osteochondroma (8%) mostly in the femur, giant cell tumors (7%) mostly in the knee, and Ewing's sarcoma (6%) mostly in the axial skeleton. Conclusion: Even though a some of the tumors have a predilection for certain localizations in the human body, they may differ in the middle-eastern population. One must also pay attention to the higher rates of malignancies as compared with other cohorts.

Indexed as

bone metastasisbone tumorsepidemiologyEwing's sarcomaMiddle-Eastosteosarcoma

Identifiers

PMID37752923
PMCPMC10518824

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.